Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan.

Stephen H Landy1, Judy E McGinnis, Susan A McDonald

  • 1Wesley Headache and Neurology Clinic, Memphis, TN 38018, USA.

Headache
|April 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Headache-related disability as a function of migraine aura: A daily diary study.

Headache·2024
Same author

Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability.

Epilepsy research·2014
Same author

Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium.

Journal of women's health (2002)·2014
Same author

Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study.

Cephalalgia : an international journal of headache·2013
Same author

Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination.

Headache·2013
Same author

A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.

Headache·2013

A lower dose of subcutaneous sumatriptan (3 mg) was preferred by most patients over the standard 6 mg dose. This 3 mg dose demonstrated comparable efficacy with improved tolerability for migraine relief.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Subcutaneous sumatriptan (6 mg) is an effective migraine treatment.
  • Some patients experience unwanted side effects with the 6 mg dose, leading to avoidance.

Purpose of the Study:

  • To evaluate the efficacy and patient preference of a lower dose (3 mg) of subcutaneous sumatriptan for moderate to severe migraine attacks.

Main Methods:

  • A study involving 30 migraine patients compared patient preference between 3 mg and 6 mg subcutaneous sumatriptan injections.
  • Key endpoints included pain freedom at various time points, sustained pain relief, patient satisfaction, and a combined efficacy/tolerability measure.

Main Results:

  • Eighty percent of patients preferred the 3 mg dose over the 6 mg dose.

Related Experiment Videos

  • Pain freedom rates at 2 hours were high for both doses (87% for 3 mg vs. 80% for 6 mg).
  • The 3 mg dose showed superior results in a combined endpoint assessing efficacy and lack of significant side effects.

    • Conclusions:

    • A 3 mg dose of subcutaneous sumatriptan offers a potentially beneficial alternative for migraine patients, balancing efficacy with improved tolerability.
    • Considering both efficacy and side effect profiles provides a more clinically meaningful assessment of migraine treatments.